Brief: Antengene Says ATG-022 Granted Breakthrough Therapy Designation For Gastric Cancer By Center For Drug Evaluation Of China NMPA
19/08/2025 11:00
Aug 19 (Reuters) - Antengene Corp Ltd 6996.HK: ATG-022 GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR GASTRIC CANCER BY CENTER FOR DRUG EVALUATION (CDE) OF CHINA NMPA Further company coverage: 6996.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106